Lantheus Holdings, Inc., an established company engaged in providing imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, recently announced its first patient has been dosed in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells, for its potential to identify patients who will respond to checkpoint inhibitor therapies.
To
read more please visit:
Source: Lantheus